אקספוביו Israeli - Kiebrania - Ministry of Health

אקספוביו

promedico ltd - selinexor - טבליה - selinexor 20 mg - selinexor

רפמיון תמיסה Israeli - Kiebrania - Ministry of Health

רפמיון תמיסה

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ארומזין Israeli - Kiebrania - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

וילאט 1000 Israeli - Kiebrania - Ministry of Health

וילאט 1000

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

וילאט 500 Israeli - Kiebrania - Ministry of Health

וילאט 500

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

רטרוביר לאינפוזיה תוך ורידית Israeli - Kiebrania - Ministry of Health

רטרוביר לאינפוזיה תוך ורידית

glaxo smith kline (israel) ltd - zidovudine - תמיסה לאינפוזיה - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids related complex (arc) who are unable to take retrovir oral formulations.

סיזוניק Israeli - Kiebrania - Ministry of Health

סיזוניק

salomon,levin & elstein ltd - ethinylestradiol 0.01 mg; ethinylestradiol 0.03 mg - tablets - ethinylestradiol - seasonique is indicated for use by women to prevent pregnancy.

סיזוניק L Israeli - Kiebrania - Ministry of Health

סיזוניק l

salomon,levin & elstein ltd - ethinylestradiol 0.01 mg; ethinylestradiol 0.02 mg - tablets - ethinylestradiol - seasonique l is indicated for use by women to prevent pregnancy.

ליויאל 2.5 מג Israeli - Kiebrania - Ministry of Health

ליויאל 2.5 מג

organon pharma israel ltd., israel - tibolone - טבליה - tibolone 2.5 mg - tibolone - tibolone - complaints resulting from the natural or artificial menopause. prevention of osteoporosis in estrogen deficiency states. treatment of estrogen deficiency symptoms in postmenopausal women.

טייקרב Israeli - Kiebrania - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.